18938-60-8

Basic information

• Product Name: Boc-Tyr-OtBu
• Synonyms: Boc-Tyr-OtBu;(S)-2-[(tert-Butoxycarbonyl)amino]-3-(4-hydroxyphenyl)propionic acid tert-butyl ester;Boc-L-tyrosine tert-butyl ester;N-[(1,1-Dimethylethoxy)carbonyl]-L-tyrosine 1,1-dimethylethyl ester;L-Tyrosine, N-[(1,1-dimethylethoxy)carbonyl]-, 1,1-dimethylethyl ester;(Tert-Butoxy)Carbonyl Tyr-OtBu
• CAS NO: 18938-60-8
• Molecular Formula: C₁₈H₂₇NO₅
• Molecular Weight: 337.41068
• Mol File: 18938-60-8.mol

Chemical Properties

• Melting Point: 111-112 °C(Solv: ligroine (8032-32-4); ethyl acetate (141-78-6))
• Boiling Point: 476.0±40.0 °C(Predicted)
• Appearance: /
• Density: 1.117±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 9.75±0.15(Predicted)
• CAS DataBase Reference: Boc-Tyr-OtBu(CAS DataBase Reference)
• NIST Chemistry Reference: Boc-Tyr-OtBu(18938-60-8)
• EPA Substance Registry System: Boc-Tyr-OtBu(18938-60-8)

Safety Data

• Hazardous Substances Data: 18938-60-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical and Biotechnology Research:
Boc-Tyr-OtBu is used as a key intermediate in the synthesis of peptides for various applications in pharmaceuticals and biotechnology. Its protective groups ensure the correct formation of peptide bonds and prevent side reactions, which is crucial for the development of effective and specific drug candidates.
Used in Organic Synthesis:
In the field of organic synthesis, Boc-Tyr-OtBu is used as a building block for the creation of complex organic molecules. The presence of the Boc and OtBu groups allows for controlled reactions, enabling chemists to construct molecules with specific structures and functionalities.
Used in Peptide Synthesis:
Boc-Tyr-OtBu is used as a protected amino acid in the stepwise assembly of peptide chains. The protective groups are strategically removed at appropriate stages of the synthesis to allow for the formation of peptide bonds, ultimately leading to the desired peptide sequence. This method ensures the correct sequence and conformation of the peptide, which is vital for its biological activity and therapeutic potential.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 16874-12-7 Tyr(tBu) 
• 3978-80-1 Boc-Tyr-OH 
• 80971-82-0 (S)-3-(4-acetoxyphenyl)-2-[N-(tert.butoxycarbonyl)amino]propionic acid 
• 60-18-4 L-tyrosine 
• 507-19-7 t-butyl bromide 
• 75-65-0 tert-butyl alcohol 
• 98946-18-0 tert-Butyl 2,2,2-trichloroacetimidate 
• 1070-19-5 N-(tert-butyloxycarbonyl) azide 

Downstream Products

• 542-78-9 Malondialdehyde 
• 351534-61-7 3-nitro-N-Boc-L-tyrosine tert-butyl ester 
• 351534-62-8 3,3'-di-N-Boc-L-tyrosine tert-butyl ester 
• 1425708-10-6 (S)-(+)-6-(4-(2-[4-(2-tert-butoxycarbonyl-2-tert-butoxycarbonylaminoethyl)phenoxy]ethoxysulfonyl)phenyl)hexanoic acid methyl ester 
• 1425708-12-8 (S)-(+)-6-(4-[2-[4-(2-tert-butoxycarbonyl-2-tert-butoxycarbonylaminoethyl)phenoxy]ethoxysulfonyl]phenyl)hexanoic acid 
• 1425708-15-1 (S)-(+)-2-tert-butoxycarbonylamino-3-[4-(2-fluoroethoxy)phenyl]propionic acid tert-butyl ester 
• 1214908-96-9 (S)-(+)-2-tert-butoxycarbonylamino-3-[4-(2-hydroxyethoxy)phenyl]propionic acid tert-butyl ester 
• 1188292-64-9 tert-butyl (S)-2-((tert-butoxycarbonyl)amino)-3-(4-(prop-2-yn-1-yloxy)phenyl)propanoate 
• 1443792-20-8 tert-butyl (S)-3-(4-(5-bromopyrimidin-2-yl)phenyl)-2-(5-(tert-butyl)thiophene-2-carboxamido)propanoate 
• 1207986-88-6 (S)-tert-butyl 2-((tert-butoxycarbonyl)amino)-3-(4-(prop-2-yn-1-yloxy)phenyl)propanoate 
• 1609554-80-4 tert-butyl (2S)-2-((2S)-2-((2S,4S)-4-allyl-1-((2S)-2-((2S)-2-((tert-butoxycarbonyl)(methyl)amino)propanamido)-3,3-dimethylbutanoyl)pyrrolidine-2-carboxamido)-3-(naphthalen-2-yl)propanamido)-3-(4-(prop-2-yn-1-yloxy)phenyl)propanoate 
• 60-18-4 L-tyrosine 

Relevant articles and documents

Synthesis and preliminary biological evaluation of O-2((2-[ 18F]fluoroethyl)methylamino)ethyltyrosine ([18F]FEMAET) as a potential cationic amino acid PET tracer for tumor imaging

Amino acid transport is an attractive target for oncologic imaging. Despite a high demand of cancer cells for cationic amino acids, their potential as PET probes remains unexplored. Arginine, in particular, is involved in a number of biosynthetic pathways

Facile synthesis of sulfotyrosine-containing α-conotoxins

α-Conotoxins (Ctx) can selectively target distinct subtypes of nicotinic acetylcholine receptors (nAChRs), which are closely related to a number of neurological diseases, and they have been considered as ideal probes and model peptide drugs. Sulfotyrosine

Development of a Photoactivatable Protein Phosphatase-1-Disrupting Peptide

We describe here the development of a photoreleasable version of a protein phosphatase-1 (PP1)-disrupting peptide (PDP-Nal) that triggers protein phosphatase-1 activity. PDP-Nal is a 23 mer that binds to PP1 through several interactions. It was photocaged

DIMETHYLAMINOETHANOL SALT OF A GLP-1 RECEPTOR MODULATOR

Crystalline 2-hydroxy-N,N-dimethylethanaminium 1 -(2-(5-(tert-butyl) -thiophene-2-carboxamido)-3-(4-(5-(4'-ethyl-[1,1'-bi(cyclohexan)]-3- en-4-yl)pyrimidin-2-yl)phenyl)propanoyl)azetidine-3-carboxylate salt, and methods related to synthesis and therapeuti

Base/Cryptand/Metal-Free Automated Nucleophilic Radiofluorination of [18F]FDOPA from Iodonium Salts: Importance of Hydrogen Carbonate Counterion

As evidenced by the number of publications and patents published in the last years, the radiosynthesis of 6-[18F]fluoro-3,4-dihydroxy-L-phenylalanine ([18F]FDOPA) using the nucleophilic [18F]F- process remains currently a challenge for the radiochemists scientific community even if promising methods for the radiofluorination of electron-rich aromatic structures were recently developed from arylboronate, arylstannane or iodonium salt precursors. In such context, based on the use of an iodonium triflate salt precursor, we optimized a fast and efficient radiofluorination route fully automated and free from any base, cryptand or metal catalyst for the radiosynthesis of [18F]FDOPA. Using this method, this clinically relevant radiotracer was produced in 64 min, 27–38 % RCY d.c. (n = 5), >99 % RCP, >99 % ee., and high Am 170–230 GBq/μmol. In addition, this optimization study clearly highlighted the important role of a triflate-hydrogen carbonate counterion exchange during the radiolabeling process to achieve high fluorine-18 incorporation yields.

Development of a Kilogram-Scale Synthesis of a Novel Anti-HCV Agent, CH4930808

Herein, we report the kilogram-scale synthesis of CH4930808 (1), a novel anti-hepatitis C virus agent. While pursuing improved productivity using many through-process strategies, we conducted scrupulous impurity control. Finally, we successfully developed

NURR1:RXR ACTIVATING COMPOUNDS FOR SIMULTANEOUS TREATMENT OF SYMPTOMS AND PATHOLOGY OF PARKINSON'S DISEASE

The invention provides a series of substituted aryl pyrimidine compounds and the use of these compounds as therapeutics to treat or prevent neurodegenerative disorders, including Parkinson's disease. Compounds of the invention are also able to treat the s

THIAZOLIDINONE COMPOUNDS AND USE THEREOF

A pharmaceutical composition containing a compound of Formula (I) for treating an opioid receptor-associated condition. Also disclosed is a method for treating an opioid receptor-associated condition using such a compound. Further disclosed are two sets of thiazolidinone compounds of formula (I): (i) compounds each having an enantiomeric excess greater than 90% and (ii) compounds each being substituted with deuterium.

COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACIDS AND POLYPEPTIDES

Disclosed herein are non-natural amino acids and polypeptides that include at least one non-natural amino acid, and methods for making such non-natural amino acids and polypeptides. The non-natural amino acids, by themselves or as a part of a polypeptide, can include a wide range of possible functionalities, but typical have at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Also disclosed herein are non-natural amino acid polypeptides that are further modified post-translationally, methods for effecting such modifications, and methods for purifying such polypeptides. Typically, the modified non-natural amino acid polypeptides include at least one oximine, carbonyl, dicarbonyl, and/or hydroxylamine group. Further disclosed are methods for using such non-natural amino acid polypeptides and modified non-natural amino acid polypeptides, including therapeutic, diagnostic, and other biotechnology uses.

NOVEL GLP-1 RECEPTOR MODULATORS

Compounds are provided that modulate the glucagon-like peptide 1 (GLP-1) receptor, as well as methods of their synthesis, and methods of their therapeutic and/or prophylactic use. Such compounds can act as modulators or potentiators of GLP-1 receptor on their own, or with incretin peptides such as GLP-1(7-36), GLP-1(9-36), and oxyntomodulin, or with peptide-based therapies, such as exenatide and liraglutide, and have the following general structure (where "?" represents either or both the R and S form of the compound): where A, B, C, R1, R2, R3, R4, R5, n, p and q are as defined herein.